 |
|
|
OsteoCorp, Inc. is an emerging specialty pharmaceutical |
 |
OsteoCorp’s products represent the first of a newly identified class of bone anabolic for which it has exclusive worldwide patent rights from the Baylor College of Medicine to their use as a therapeutic to prevent and treat bone disorders. The company’s technology and product platform are based on the discovery that bone formation and resorption are controlled by the sympathetic nervous system: Bone-forming osteoblasts possess ß2-adrenergic receptors that comprise a newly discovered ligand-receptor complex to regulate bone density in skeletal tissue. OsteoCorp will enter into partnerships with other companies to advance its technology and product development. |
|
Founded in 2006, the San Francisco Bay Area company is developing and commercializing Osoprol-CR™ and Osoprol-TD™— proprietary oral and transdermal formulations of its lead bone beta-blocker drug for increasing bone mineral density and reducing fracture risk.
|
||||||||||||
